FROM PUBLIC EVENTS · 2026-11-15

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Early clinical · first deals Licensed its phase 2 autoimmune candidate to a US company and is developing follow-on candidates.

  • Licensed the SYK inhibitor cevidoplenib to a US company in a deal worth up to about KRW 1 trillion. Source

Roles often seen at this stageResearch & development · Clinical & PV · BD & licensing

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-15

Oscotec

A small-molecule drug developer that licensed its autoimmune candidate cevidoplenib to a US company in 2026.

Cevidoplenib

Phase 2

SYK inhibitor that completed global phase 2 studies, including in immune thrombocytopenia, and was licensed to a US company for development and commercialisation.

Completion reported

Licensed global exclusive rights to cevidoplenib to a US company in a deal worth up to about KRW 1 trillion.

Official role guide

Oscotec careers

Current availability unconfirmed

Observed 2026-11-15

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 2

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. 오스코텍, 美아지오스에 자가면역질환 치료제 후보물질 최대 9600억원에 기술수출 ↗한국경제 · Published 2026-06-01 · Sources checked 2026-11-15 · Original unavailable
  2. 오스코텍, 美 아지오스와 SYK 억제제 '세비도플레닙' 9620억원 규모 L/O ↗더바이오 · Published Date unconfirmed · Sources checked 2026-11-15 · Original unavailable